cabozantinib,atezolizumab
roche
['cabo ', 'contact-03', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo']
addressing question of rechallenging with pd-(l)1 inhibitor, primary pfs analysis of contact-03 demonstrates similar pfs with hr 1.03 for atezo+cabo vs cabo after prior ici in mrcc across all subgroups. #asco23 
DAVA Oncology is a strategic consulting company that offers numerous products and services customized to fit biopharmaceutical drug development needs.